Patent · US Expired

Adenovirus vectors specific for cells expressing androgen receptor and methods of use thereof

US6436394B1 · kind B1 · utility

50Cited by
11References
26Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJul 11, 2000
Grant dateAug 20, 2002
Priority date
Expiry dateJul 11, 2020

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2830/008
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Replication-competent adenovirus vectors specific for cells which allow a probasin transcriptional response element (PB-TRE) to function, such as cells which express the androgen receptor (AR), and methods of use of such viruses are provided. These viruses comprise and adenoviral gene under control of a transcription regulatory portion of a PB-TRE, which is in turn dependent upon AR expression. The gene can be, for example, a gene required for viral replication or the adenovirus death protein gene (ADP). The viruses can also comprise at least one additional adenoviral gene under control of at least one additional prostate-specific transcriptional response element, such as that controlling prostate-specific antigen expression (PSA-TRE). Thus, virus replication can be restricted to target cells exhibiting prostate-specific gene expression, particularly prostate carcinoma cells. An adenovirus of the present invention can further comprise a heterologus gene such as a reporter under transcriptional control of a PB-TRE. The adenovirus vectors can be used to detect and monitor samples for the presence of prostate cells as well as to selectively kill malignant cells producing prostate-spec…

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.